TY  - GEN
AU  - Dvorak,Christopher C
AU  - Satwani,Prakash
AU  - Stieglitz,Elliot
AU  - Cairo,Mitchell S
AU  - Dang,Ha
AU  - Pei,Qinglin
AU  - Gao,Yun
AU  - Wall,Donna
AU  - Mazor,Tali
AU  - Olshen,Adam B
AU  - Parker,Joel S
AU  - Kahwash,Samir
AU  - Hirsch,Betsy
AU  - Raimondi,Susana
AU  - Patel,Neil
AU  - Skeens,Micah
AU  - Cooper,Todd
AU  - Mehta,Parinda A
AU  - Grupp,Stephan A
AU  - Loh,Mignon L
TI  - Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study
SN  - 1545-5017
PY  - 2019///0506
KW  - Busulfan
KW  - administration & dosage
KW  - Child
KW  - Child, Preschool
KW  - Female
KW  - Follow-Up Studies
KW  - Graft Rejection
KW  - drug therapy
KW  - Graft vs Host Disease
KW  - Hematopoietic Stem Cell Transplantation
KW  - adverse effects
KW  - Humans
KW  - Infant
KW  - Infant, Newborn
KW  - Leukemia, Myelomonocytic, Juvenile
KW  - complications
KW  - Male
KW  - Myeloablative Agonists
KW  - Prognosis
KW  - Transplantation Conditioning
KW  - Vidarabine
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
UR  - https://doi.org/10.1002/pbc.27034
ER  -